How are energy investors positioned?
Adicet Bio, Inc. (Market cap: $75.8M), a biopharmaceutical company currently rated ’FAIR’ by InvestingPro’s Financial Health scoring system, has announced updates on the enrollment of its clinical programs at the Guggenheim Securities SMID Cap Biotech Conference in New York City. The company, which maintains a strong liquidity position with a current ratio of 10.64, is actively enrolling patients for several trials, including its ADI-001 for Lupus Nephritis and ADI-270 for renal cell carcinoma.
The Phase 1 Lupus Nephritis clinical trial of ADI-001 has enrolled 3 patients since the first patient was dosed in November 2024. Approximately 12 sites have been activated for this trial, with more expected soon. Preliminary results from this trial are anticipated in the first half of 2025, with the next earnings update scheduled for March 12, 2025. According to InvestingPro analysis, while the company holds more cash than debt on its balance sheet, it is quickly burning through its cash reserves.
In addition to Lupus Nephritis, Adicet plans to initiate Phase 1 enrollment for ADI-001 in other autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, and stiff person syndrome within the first quarter of 2025. The company expects to share preliminary data from these patient cohorts in the second half of 2025. Enrollment for a trial in anti-neutrophil cytoplasmic autoantibody associated vasculitis is projected to start in the second half of 2025.
For the ADI-270 program targeting metastatic/advanced clear cell renal cell carcinoma, 3 patients have been enrolled in the Phase 1 trial since the first patient was dosed in December 2024. With approximately 7 sites currently activated and more expected, preliminary results from this trial are also expected in the first half of 2025.
This information is based on a recent SEC filing by Adicet Bio, Inc. and reflects the company’s expectations and projections as of the date of the report. Despite the stock’s significant decline of over 70% in the past year, InvestingPro’s Fair Value analysis suggests the stock may be undervalued at current levels. Investors seeking deeper insights can access comprehensive analysis and additional ProTips through the detailed Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Adicet Bio, Inc. has been active on multiple fronts. The biotechnology company has initiated a Phase 1 clinical trial for a potential treatment of metastatic/advanced clear cell renal cell carcinoma (ccRCC) with its gamma delta CAR T cell therapy candidate, ADI-270. Early-stage clinical data from this trial is expected in the first half of 2025.
The company also announced the appointment of Dr. Julie Maltzman as its new Chief Medical (TASE:PMCN) Officer, who will lead the firm’s clinical development strategy. In a financial move, Adicet Bio has successfully settled its outstanding debts with Banc of California (NYSE:BANC), concluding its financial obligations under the original Loan and Security Agreement.
Moreover, Adicet Bio has initiated another Phase 1 trial for its novel CAR T cell therapy, ADI-270, aimed at treating advanced ccRCC. The company has also commenced a Phase 1 clinical trial for lupus nephritis (LN) patients, exploring the potential of its investigational therapy ADI-001. Preliminary data from this trial is also anticipated in the first half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.